Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Characterization of a recombinant canine coronavirus with a distinct receptor-binding (S1) domain

Andrew D. Regana,1, Jean K. Milleta,1, Long Ping V. Tsea, Zach Chillaga, Vera D. Rinaldi a, Beth N. Licitra a, Edward J. Dubovib, Christopher D. Townc, Gary R. Whittakera,∗

a Department of Microbiology and Immunology, Veterinary Medical Center, Cornell University, Ithaca, NY 14853, United States
b Animal Health Diagnostic Center, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, United States
c J. Craig Venter Sequencing Center, Rockville, MD, United States

Article info
Article history:
Received 29 February 2012
Returned to author for revisions 30 March 2012
Accepted 17 April 2012
Available online 18 May 2012

Keywords:
Canine coronavirus
Spike protein
Receptor binding domain
Recombination

Abstract
Canine alphacoronaviruses (CCoV) exist in two serotypes, type I and II, both of which can cause severe gastroenteritis. Here, we characterize a canine alphacoronavirus, designated CCoV-A76, first isolated in 1976. Serological studies show that CCoV-A76 is distinct from other CCoVs, such as the prototype CCoV-1-71. Efficient replication of CCoV-A76 is restricted to canine cell lines, in contrast to the prototypical type II strain CCoV-1-71 that more efficiently replicates in feline cells. CCoV-A76 can use canine aminopeptidase N (cAPN) receptor for infection of cells, but was unable to use feline APN (fAPN). In contrast, CCoV-1-71 can utilize both. Genomic analysis shows that CCoV-A76 possesses a distinct spike, which is the result of a recombination between type I and type II CCoV, that occurred between the N- and C-terminal domains (NTD and C-domain) of the S1 subunit. These data suggest that CCoV-A76 represents a recombinant coronavirus form, with distinct host cell tropism.

Introduction
Coronaviruses are single-stranded RNA viruses which infect humans and a variety of non-primate mammals, including canines (Lai and Holmes, 2001; Perlman et al., 2008). Research on these viruses has greatly increased since 2003 due to the severe acute respiratory syndrome (SARS) pandemic caused by a zoonotic transmission of an animal coronavirus into the human population (Eaton and Wang, 2007). Coronaviruses are phylogenetically divided into several genera termed alpha, beta, gamma and delta (King et al., 2011). There are two known coronavirus species that infect dogs: a newly identified betacoronavirus termed canine respiratory coronavirus (CRCoV), and a more characterized alphacoronavirus termed canine enteric coronavirus CCoV (Decaro and Buonavoglia, 2008). Within the CCoV alphacoronavirus species, there are two distinct serotypes (type I and type II), with both forms of CCoV transmitted via a fecal–oral route (Decaro and Buonavoglia, 2008). CCoV is usually thought to cause only mild to inapparent enteritis (Pollock and Carmichael, 1983). However, in some cases CCoV infection can be fatal in young dogs, in particular when coinfections occur with canine parvovirus or other pathogens (Pratelli et al., 1999). In recent years, an increasing number of highly virulent CCoV infections have also been reported in healthy adult dogs without apparent coinfections (Buonavoglia et al., 2006; Decaro et al., 2007; Escutenaire et al., 2007; Evermann et al., 2005; Naylor et al., 2002; Sanchez-Morgado et al., 2004; Zappulli et al., 2008). In some of these cases, these new pathogenic viruses are able to spread to other organs and are thought to be novel recombinant forms of CCoV, such as the CCoV type IIB viruses that are more closely related to transmissible gastroenteritis virus (TGEV) of pigs (Decaro and Buonavoglia, 2008; Decaro et al., 2009; Erles and Brownlie, 2009; Ntafis et al., 2011). The emergence of such highly virulent isolates of CCoV has significantly renewed interest in this group of viruses.

CCoV particles are composed of four major structural proteins termed spike (S), envelope (E), membrane (M) and nucleocapsid (N) (Hogue and Machamer, 2008). CCoV type I and CCoV type II are closely related to each other except for markedly different spike proteins and the presence of an additional open reading frame (ORF3) in CCoV type I isolates (Lorusso et al., 2008). This is analogous to the situation with feline coronavirus (FCoV), which also exist as two serotypes (type I FCoV and type II FCoV) based on distinct spike proteins (Hajjema, et al., 2007). It has been proposed that type I CCoVs and FCoVs evolved from a common ancestral virus, and that the canine and feline type II lineages arose from multiple recombination events with an unidentified genetic source (Lorusso et al., 2008). Also closely related to the
CCoV/FCoV type II lineage is TGEV, whose origin is unclear but which may have arisen from zoonotic transfer of a type II CCoV to pigs (LorussO et al., 2008).

The coronavirus spike protein is a major antigenic determinant and is also responsible for host cell receptor binding and viral entry (Gallagher and Buchmeier, 2001). Aminopeptidase N (APN) has been shown to act as a cellular receptor for FCoV, CCoV and TGEV (Wentworth and Holmes, 2001). Although each virus would be assumed to utilize a species-specific homolog in its respective host during in vivo infection, the feline homolog (fAPN) can act, in vitro, as a common receptor for type II FCoV, type II CCoV and TGEV (Tresnan et al., 1996). This situation is unlike the one found for most other coronaviruses, which have highly species-specific receptors. This broad receptor binding ability likely plays a role in the zoonotic transfer and genetic recombination events that have defined the evolution of animal alphacoronaviruses. In the case of the serotype I FCoV/CCoV group, the receptor determinants are much less certain. While there is some evidence for fAPN as an FCoV type I receptor (Tresnan et al., 1996), other studies have concluded that there is a distinct receptor for FCoV type I (Dye et al., 2007; Hohdatsu et al., 1998). Receptor determinants for CCoV type I remain essentially unknown. In addition to a specific proteinaceous receptor, there are indications that lectin-based interactions via sugar moieties, on either the virus or the host, may play a role in the receptor-binding complex for FCoV types I and II and TGEV (Krempl et al., 1997; Regan et al., 2010; Regan and Whittaker, 2008; Schultz et al., 1996; Van Hamme et al., 2011).

Most CCoVs isolated to date are type II viruses. These are easily cultivated in vitro (Pollock and Carmichael, 1983), with canine A-72 cells typically used for virus isolation. In contrast, type I CCoVs have yet to be easily cultivated in cell culture, and were only recently discovered by reverse-transcription polymerase chain reaction from canine fecal RNA (Pratelli et al., 2003). CCoV-A76 was isolated from a closed breeding colony of Beagles at the James A. Baker Institute for Animal Health (Cornell University, Ithaca, NY) in 1976. The dogs presented primarily with enteritis, but the virus also appeared to cause additional clinical signs, with significant morbidity in litters of newborn pups exposed to the virus, and with abortions in some pregnant bitches (Carmichael, 1978). The virus was readily isolated, and was later noted to possess distinct antigenic characteristics as compared to other type II CCoV isolates (Corapi et al., 1992). CCoV-A76 was archived at the Animal Health Diagnostic Center (College of Veterinary Medicine, Cornell University, Ithaca, NY) and further characterization was not performed. In light of recent interest in CCoV, we obtained this specimen from the archive for further study. Here, we report data on in vitro growth, antigenic and genomic analysis of CCoV-A76, and show that it represents a recombinant CCoV.

Results

In vitro cultivation of CCoV-A76

A previous study indicated CCoV-A76 to be antigenically distinct from other CCoV isolates (Corapi et al., 1992), however further characterization was not reported. To perform more extensive analysis, we obtained samples of CCoV-A76 from the Animal Health Diagnostic Center (Cornell University, Ithaca, NY) and inoculated a canine cell line (A-72). Supernatant and cells were tested for viral titer by plaque assay on A-72 cells, demonstrating that CCoV-A76 infection produces large quantities of extracellular particles (Fig. 1A). This is similar to results observed with other viruses such as type II CCoV-1-71, type II FCoV-1146, and TGEV-Purdue, but different than virus isolates such as type I FCoV-TN406 (FIPV-Black), which exclusively produce cell-associated virions (Fig. 1A). The identification of A76 as a coronavirus was confirmed by immunofluorescence microscopy using the antibody FIPV3-70, a generally cross-reactive CoV nucleocapsid-specific monoclonal antibody (Fig. 1B).

Antigenic analysis of CCoV-A76

The antigenic characteristics of CCoV-A76, along with other alphacoronaviruses, were further analyzed by immunofluorescence microscopy using polyclonal anti-CCoV sera, with mAb FIPV3-70, and with a panel of monoclonal antibodies previously tested against CCoV-A76 (anti-nucleocapsid (N): 16C11.13, 17B7.1; anti-spike (S): 18A7.4, 18H9.1, 19G11.10, 21D10.2, 22G6.4, 23A1.8) (Corapi et al., 1992) (Fig. 2A and B). The CCoV type II isolates CCoV-1-71, CCoV-S378, CCoV-K378, the FCoV type II isolates FCoV-1146, FCoV-1683, FCoV-DF2, the FCoV type I isolate FCoV-TN406 (FIPV-Black), and TGEV-Purdue were all antigenically analyzed for comparison. The distantly related betacoronavirus MHV-A59 was also tested as an outlier control. The polyclonal anti-CCoV sera and all three anti-nucleocapsid mAbs reacted strongly with all alphacoronavirus isolates tested including CCoV-A76, but did not react with MHV-A59 (Fig. 2B). All six anti-spike mAbs reacted with FCoV-1146, FCoV-1683, FCoV-DF2 (Fig. 2B). Four of the six anti-spike mAbs (18A7.4, 19G11.10, 22G6.4, 23A1.8) reacted with the CCoV type II isolates CCoV-1-71, CCoV-S378, CCoV-K378 and TGEV-Purdue.
None of the six anti-spike mAbs cross-reacted with CCoV-A76 (Fig. 2B).

Cell tropism of CCoV-A76

To further characterize the in vitro growth characteristics of CCoV-A76, multiple cell lines including canine (A-72, MDCK, Cf2Th, CDKE-2), feline (CRFK, AK-D, Fc2Lu, FMEC), porcine (LLC-PK1), and murine (NIH-3T3) were inoculated with CCoV-A76 at an MOI of 1 (Fig. 3A and B). All cell lines were also inoculated with closely related CCoV type II isolates (CCoV-1-71, CCoV-S378, CCoV-K378), FCoV type II isolates (FCoV-1146, FCoV-1683, FCoV-DF2), FCoV type I isolate (FCoV-TN406), and TGEV-Purdue. The CCoV type II isolates CCoV-1-71, CCoV-S378 and CCoV-K378 infected all feline cell lines tested, but did not infect any canine or porcine cell lines, except A-72 cells at a low efficiency (30, 27 and 22% respectively) (Fig. 3B). The FCoV type II isolates FCoV-1146, FCoV-1683 and FCoV-DF2 also efficiently infected all feline cell lines and A-72 cells, but not other canine or porcine cell lines tested (Fig. 3B). The FCoV type I isolate FIPV-TN406 infected the feline cell line AK-D only (Fig. 3B). TGEV-Purdue efficiently infected the porcine LLC-PK1 cells, and also infected all feline cell lines and A-72 cells at overall reduced efficiency. CCoV-A76 efficiently infected all canine cell lines tested, but was unable to infect any feline cell lines. CCoV-A76 infected LLC-PK1 cells at a reduced efficiency (24%). None of the viruses tested infected the murine NIH-3T3 cell line (Fig. 3B).

Use of canine and feline APN as a CCoV-A76 receptor

Because of the distinct tropism for CCoV-A76 for canine vs. feline cells, we examined the utilization of canine vs. feline APN as a CCoV-A76 receptor (Fig. 4). Non-permissive BHK cells were transfected to express either cAPN or fAPN, and infected with CCoV-A76, along with CCoV-1-71 and FCoV-1683 as controls. CCoV-A76 was able to infect BHK cells expressing cAPN, but was unable to infect cells expressing fAPN (Fig. 4A). In contrast, both CCoV-1-71 and FCoV-1683 were able to infect cells expressing either cAPN or fAPN (Fig. 4B and C).

Sequencing and phylogenetic analysis of CCoV-A76 genome

Viral RNA was purified from CCoV-A76 particles and subjected to genome sequencing (C Town, unpublished results). Most viral ORFs were successfully sequenced and annotated, with the exception of ORF1ab, where only the 3' end of ORF1ab sequence has been obtained. In general, the sequences for all non-structural and structural proteins, except for the spike, were more related to type II CCoV than to type I (Supplementary Fig. 1), suggesting that...
Intriguingly, this analysis has shown that the S protein has a sequence that would correspond to an intermediate between prototypical type I and type II CCoVs (CCoV-Elmo/02 and CCoV-1-71 respectively, Supplementary Fig. 1).

Phylogenetic analysis of CCoV-A76 spike

Because the CCoV-A76 spike sequence did not cluster well with either type I or II CCoVs, and since the spike protein is a determinant of cell tropism and viral pathogenesis, we focused on the spike protein sequence to perform a more extensive phylogenetic analysis (Fig. 5). Overall, the complete spike protein was distinct from other alphacoronaviruses and did not cluster with either type I or type II CCoVs (CCoV-Elmo/02 and CCoV-1-71 respectively, Supplementary Fig. 1).

Discussion

In a survey of canine coronaviruses stored at Cornell University, we carried out a retrospective analysis of a CCoV first isolated in 1976 (CCoV-A76), which has previously been shown to be antigendically distinct from typical type II CCoVs (Corapi et al., 1992). Immunofluorescence experiments have shown that a panel of antibodies specific for the coronavirus N protein cross reacts with CCoV-A76, but a panel of antibodies specific for the type II FCoV S protein fails to cross react with the virus. Importantly, while both CCoV-A76 and CCoV-1-71-like viruses can infect canine A-72 cells, CCoV-A76 shows distinct and pronounced tropism for a variety of additional dog cell lines (e.g. MDCK), as well as pig cell lines (e.g. LLC-PK1) that the prototypical 1–71-like CCoVs fail to infect. Additionally, CCoV-A76 fails to infect cells of cat origin (e.g. CRFK, AK-D), which are very efficiently infected by cluster with 1–71 (Fig. 5D). In contrast, the CCoV-A76 C-domain was divergent and did not clearly cluster with any characterized alphacoronavirus (Fig. 5E). Overall, these data indicate that the CCoV-A76 spike gene is probably a recombinant of a type I CCoV with a type II CCoV spike, with a recombination site located between the NTD and C-domain of S1. To determine possible recombination sites within S1, we used the BOOTSCAN/RESCAN method to identify recombination events and breakpoints in the CCoV-A76 S nucleotide sequence. This analysis confirmed the presence of recombination between the NTD and C-domain, with a breakpoint at nucleotide 890 (Fig. 6).
1–71-like CCoVs. These serological data suggested that CCoV-A76 possesses distinct characteristics setting it apart from other known CCoVs. Phylogenetic analysis of the CCoV-A76 genome shows that it is mostly related to type II CCoV, however, analysis of the spike sequence at the amino acid level places CCoV-A76 as an outlier of the CCoV group, suggesting that CCoV-A76 is genetically distinct. Notably, CCoV-A76 is genetically distinct from recently isolated highly virulent type IIb CCoV strains, such as CCoV-CB/05. CCoV-A76 S appears to be a recombinant of a type II and a type IIa CCoV, with recombination occurring between the NTD and C-domain of S1 (Fig. 7). Further proof of a recombination event occurring at the spike gene of CCoV-A76 was found by analyzing its nucleotide coding sequence. Indeed, in close proximity of the recombination breakpoint identified by the BOOTSCAN/RESCAN methodology (nucleotide 890), several stretches of nucleotides that were either identical (TCTAA, found twice at nucleotide 932 and at nucleotide 972) or near identical (ATAAAAAT at nucleotide 862 and GTAAAATG at nucleotide 990) to characterized CCoV recombination signals (TCTAA and G/CTAAAAA/GT) (Wang and Lu, 2009) have been identified (data not shown). The divergent C-domain may impart more strict species specificity to CCoV-A76, via specific interactions within the D3 domain. It is also possible that an interaction between the APN binding site and the distinct CCoV type I-like NTD found in CCoV-A76 might account for the distinct species specificity of this virus. Overall, while CCoV-A76 clearly has a recombinant origin, it should be remembered that the recombination event has not occurred within the known APN-binding domain (D3 domain, residues 526–676), but between the NTD and the C-domain (around residue 297, Fig. 7). As such, the recombination event itself is unlikely to be directly responsible for the distinct receptor-binding characteristics of CCoV-A76, which may be caused by D3 domain divergence through missense mutations or via the influence of the distinct NTD.

In the case of APN itself, previous studies have shown that molecular determinants of species specificity lie in glycosylation...
sequon differences. Comparing cAPN to fAPN using NetNGlyc glycan prediction software reveals that cAPN is more extensively glycosylated than fAPN (with cAPN having 5 potential glycosylation sites on the solvent exposed domain while fAPN has only 2). In particular, residues 291–293 were shown to control species specificity between human, porcine and feline APN (Wentworth and Holmes, 2001). However, this glycosylation sequon is absent for both fAPN and cAPN. Analysis of the spike-interacting APN domain previously shown to control species specificity for hAPN (residues 670–840) (Hegyi and Kolb, 1998) reveals the presence of a glycosylation site sequon NTS for cAPN, which is missing in fAPN (Supplementary Fig. 4). As with hAPN (Wentworth and Holmes, 2001), this sequon may control the species specificity of APN. However, the effect of this glycosylation site in the context of infection by CCoV-A76 remains to be tested experimentally.

Fig. 5. Phylogenetic analysis of CCoV-A76 spike. The phylogenetic analysis was performed using full-length coronavirus spike amino acid sequences (A), the S2 subunit sequences including the transmembrane (TM) and C-termini (CT) (B), the S1 subunit sequences (C), the S1 N-terminal domain (NTD) sequences (D), and the S1 C-terminal domain (C-domain) sequences (E). The sequences used in the analyses are represented for each tree, with the region of spike that is used shown in black, and the region not included shown in gray. The S1/S2 cleavage site of the coronavirus spike protein was used as the delineating site between S1 and S2 domains. Determination of NTD and C-domain of the CoV S1 used in the analysis was performed by alignment of individual spikes with MHV-A59 sequence, which has defined NTD and C-domain sequences. The trees were generated using ClustalX 2.1 with the Neighbor-Joining method and bootstrap values calculated from 2000 trees. Scale bars represent the estimated number of substitutions per site.
alphacoronaviruses (with the exception of HCoV-NL63, which uses ACE-2 as a receptor), the situation for the type I FCoV/CCoV lineage is less clear, with the usage of an fAPN receptor much less certain. Our data clearly indicate that CCoV-A76 is another exception to the idea that fAPN is a universal receptor within the alphacoronavirus subfamily.

Coronaviruses are known to efficiently recombine, especially within the spike gene, to modulate host range and pathogenesis (Graham and Baric, 2010). This has been most well demonstrated with the type II FCoVs, which have clearly been shown to represent a recombinant between a type I FCoV and a type II CCoV (Herrewegh et al., 1998; Vennema et al., 1998) and represent a replacement of the entire spike gene. In dogs, both type I and type II CCoVs are circulating extensively and a molecular analysis of fecal samples has revealed the simultaneous presence of CCoV type I and CCoV type II in 38/177 naturally-infected dogs (Decaro et al., 2005). Thus, a likely scenario for the emergence of CCoV-A76 is that CCoV type I and CCoV type II were both circulating in the animal breeding facilities at Cornell University in 1976, with dogs infected simultaneously with both serotypes allowing for recombination between the two distinct spike genes. In this scenario, it is interesting to note that a CCoV type I virus would have been circulating in the dog population long before the identification of the prototype CCoV type I strain Elmo/02 in 2002.

It remains unclear whether highly virulent A76-like viruses are naturally circulating in dogs, or if CCoV-A76 represents a defined recombination event, possibly with limited dog–dog transmission. Whereas most of the prototype or newly described pathogenic CCoVs have been ascribed to the CCoV type I family (e.g. CCoV-Elmo/02), the CCoV type II family (e.g. CCoV-1-71) or the CCoV type IIB family (e.g. CCoV-CB/05), a number of outbreaks of highly virulent coronavirus infection remain incompletely characterized at a molecular level. Of particular interest is a series of CCoV outbreaks of gastroenteritis in Sweden (Escutenaire et al., 2007). Four closely related CCoVs were identified, typified by the strain CCoV-Uppsala2/04. While only limited genomic analysis of these viruses was performed, it is apparent that the Uppsala2/04-like CCoVs contained an S protein with N-terminal and C-terminal domains closely related to CCoV type I and type II respectively—also indicating their possible origin from recombination between the two CCoV genotypes.

Our data provide further support for the modular nature of the coronavirus spike glycoprotein. With this in mind, it will be important to examine any outbreaks of highly virulent coronavirus infection of dogs in the context of novel recombinants between CCoV type I and type II and to consider novel recombinants between the S1 NTD and C-domain as possible zoonotic coronaviruses.

Material and methods

Cell lines

Crandell-Rees feline kidney (CRFK), feline lung (AK-D), Madin-Darby canine kidney (MDCK), porcine kidney (LLC-PK1) and rat lung (L2) cells were obtained from the American Type Culture Collection (ATCC). Canine thymus (C2Th), canine kidney (CDKE-2), and feline lung (Fc2Lu) cells were obtained from the Cornell Animal Health Diagnostic Center (Cornell University, Ithaca, NY). Canine fibroblast (A-72) cells were obtained from Dr. Colin Parrish, Baker Institute for Animal Health (Cornell University, Ithaca, NY). Polarized feline mammary epithelial cells (FMEC) were obtained from Dr. John Parker, Baker Institute for Animal Health (Cornell University, Ithaca, NY). Murine NIH-3T3 cells were obtained from Dr. Richard Cerione, College of Veterinary Medicine, Department of...
Molecular Medicine (Cornell University, Ithaca, NY). All cells were grown at 37°C with an atmosphere of 5% CO₂, in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 10 mM glutamine, 100 U/mL penicillin and 10 μg/mL streptomycin.

Antibodies

The mouse monoclonal anti-coronavirus antibody FIPV3-70 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Feline polyclonal anti-CCoV antisera and anti-feline FITC was obtained from Veterinary Medical Research and Development Inc. (Pullman, WA). Mouse monoclonal anti-fCoV nucleocapsid antibodies 16C11.13 and 17B7.1, and mouse monoclonal anti-fCoV spike antibodies 18A7.4, 18H9.1, 19G11.10, 21D10.2, 22G6.4, and 23A1.8 were obtained from the Cornell Animal Health Diagnostic Center (Cornell University, Ithaca, NY). Mouse monoclonal anti-FLAG-M2 was bought from Sigma Aldrich and mouse monoclonal anti-FAPN (RG4) was provided by (Hohdatsu et al. (1998)).

Viruses

CCoV-A76 (also referred to as CCoV-A76/5), CCoV-I-71, CCoV-K378 (CCoV-K378/6), CCoV-S378 (CCoV-S378/3), FCoV-1683 (FECV WSU 79-1683), FCoV-DF2 (FIPv-DF2), FCoV-TN406 (FIPv-Black) and TGEV-Purdue were obtained from the Cornell Animal Health Diagnostic Center (Cornell University, Ithaca, NY). FCoV-1146 (FIPv WSU 79-1146) and mouse hepatitis virus strain A59 (MHV-A59) were obtained from the ATCC. CCoV-A76 was grown in A-72 cells. CCoV-I-71, CCoV-K378 and CCoV-S378 were grown in CRFK cells. FCoV-1683, FCoV-DF2 and FCoV-TN406 were grown in AK-D cells or A-72 cells. TGEV-Purdue was grown in swine testicle (ST) cells. MHV-A59 was grown in L2 cells. All viruses (except FCoV-TN406) were grown by inoculating cells at an MOI of 0.1 and harvesting supernatant after CPE was observed in >80% of cells (typically between 36 and 48 h). Supernatant was then cleared of cellular debris with a low-speed spin at 2500 rpm for 15 min and then stored at −80°C. FCoV-TN406 was inoculated at an MOI of 1 and harvested after 48 h by scraping cells into the media, passing the mixture 5 times through a 25-gauge needle, and storing at −80°C.

Virus infection and growth assays

Viral infections were carried out by inoculating cells at the specified MOI in media as previously described except without FBS. Cells were then incubated for 60 min at 37°C with gentle rocking to allow viral adsorption. After binding, cells were washed twice with phosphate buffered saline (PBS) and replaced with standard media supplemented with 2% FBS and allowed to incubate for the specified amount of time. For growth assays, either supernatant or cells were collected and processed as described above. Plaque assays were carried out by standard methods. For infection assays, cells were fixed at either 24 h post-infection (p.i.) for FCoV-TN406, or 12 h p.i. for all other viruses. Cells were processed for immunofluorescence microscopy as previously described (Regan et al., 2008).

Microscopy

Differential interference contrast (DIC) images were generated on a Zeiss Axiovert 200 inverted microscope. Immunofluorescence images were generated on a Nikon Eclipse E600 fluorescence microscope. All images were captured on a Sensicam EM camera (PCO, Kelheim, Germany) and processed with IPLab software (BioVision Technologies, Exton, PA).

Cloning and expression of canine aminopeptidase N (cAPN)

Total RNA was extracted from A-72 cells using an RNeasy Plus Mini Kit (Qiagen). cDNA was amplified by the OneStep RT-PCR kit (Qiagen) and the desired band of molecular weight 3 kb was excised by gel purification and cloned into pTOPO using a TOP10 TA cloning kit (Invitrogen). In order to detect cAPN efficiently, a construct, pCMV-tag1-FLAG-cAPN (with a N-terminal FLAG tag) was created for expression in mammalian cells. The tag was added by cloning cAPN sequence into the pCMV-tag1 vector (Agilent). The construct was sequence confirmed by the Cornell University Life Sciences Core Laboratories Center (CLC). Expression was verified by immunofluorescence microscopy using the mouse monoclonal anti-FLAG-M2 antibodies.

RNA sequencing

Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (QIAGEN). Purified genomic RNA was reverse transcribed in an oligo-dt-primed reaction using SuperScript III (Invitrogen). Amplicons covering most of the 3' one third of the genome were generated by PCR using Accuprime (Invitrogen) and the following primer sets: A765-1B-Fwd GCTGCTCTTTACAGAGGAT and A765-S2-Rev GTAACGTGTTACAAAGGATAT and A765-S2-Fwd GGCCTTTGTGAACTTGAGCA and A765-7b-Rev ACCTGCTTACATTCTGATACA. These generated two amplicons of ~6 kb each with an overlap of ~500 bp. Amplicons were gel purified and pooled in equimolar amounts after which they were simultaneously amplified and bar-coded in two separate reactions using SISPA (http://www.biomedcentral.com/1471-2164/9/5). A pool of these and other viral samples were used to construct 454 and Illumina libraries and sequenced on their respective platforms. After sequencing, reads from each platform were deconvoluted by bar code and trimmed for quality and to remove the SISPA hexamer primer sequences. Both GS-FLX and Illumina libraries were then de novo assembled using CLC Bio’s clc_novo_assemble program. The final sequence assembly was annotated using the VIGOR pipeline (http://www.biomedcentral.com/1471-2105/11/451).

CCoV-A76 nucleotide and protein sequences accession numbers

The nucleotide sequences of the CCoV-A76 ORF1ab (partial sequence), spike (S), 3a, 3c, envelope (E), membrane (M), nucleocapsid (N), 7a and 7b genes have been deposited in the National Center for Biotechnology Information (NCBI) GenBank database under the following accession number—GenBank ID: JN856008.1. The accession numbers for the individual NCBI GenBank protein sequences of CCoV-A76 are as follows—ORF1ab GenBank ID: AEQ61967.1; S GenBank ID: AEQ61968.1; 3a GenBank ID: AEQ61969.1; 3c GenBank ID: AEQ61970.1; E GenBank ID: AEQ61971.1; M GenBank ID: AEQ61972.1; N GenBank ID: AEQ61973.1; 7a GenBank ID: AEQ61974.1; 7b GenBank ID: AEQ61975.1.

Phylogenetic and recombination analyses of CCoV-A76 spike

Phylogenetic trees were generated using the following sequences from the NCBI GenBank database—CCoV-A76 GenBank ID: AEQ61968.1; CCoV-I-71 GenBank ID: AY796289.1; CCoV-Elmo/02 GenBank ID: AY307020.1; CCoV-CB/05 GenBank ID: AA214347.1; CCoV-Giant-Panda GenBank ID: AY436337.1; FCoV-WSU-79-1683 GenBank ID: X80799.1; FCoV-WSU-79-1146 GenBank ID: YP_004070194.1; FCoV-VM GenBank ID: ACT10854.1; IBV-M41 GenBank ID: AAW33786.1; BCoV-Quebec GenBank ID: AAL40400.1; Ferret-Enteric-CoV-MSU2 GenBank ID: ADD49358.1; MHV-A59 GenBank ID: AAU06356.1; TGEV-Purdue GenBank
References

Buonavoglia, C., Decaro, N., Martella, V., Elia, G., Campo, M., Desario, C., Castagnaro, M., Tempesta, M., 2006. Canine coronavirus highly pathogenic for dogs. Emerg. Infect. Dis. Mar. 12 (3), 492–494.

Carmichael, L.E., 1978. Infectious canine enteritis caused by corona-like virus: current status and request for information. J. Infect. Dis. 137 (2), 281–298.

Herrewegh, A.A., Smeenk, I., Horzinek, M.C., Rottier, P.J., de Groot, R.J., 1998. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J. Virol. 72 (5), 4508–4514.

Evermann, J., Abbott, J.R., Han, S., 2005. Canine coronavirus-associated puppy mortality without evidence of concurrent canine parvovirus infection. J. Vet. Diagn. Invest. Nov. 17 (6), 610–614.

Gallagher, T., Buchmeier, M.J., 2001. Coronavirus spike proteins in viral entry and pathogenesis. Virology 270 (2), 371–374.

Hegyi, A., Kolb, A.F., 1998. Characterization of determinants involved in the feline infectious peritonitis virus receptor function of feline aminopeptidase N. J. Virol. 72 (7), 5318–5322.

Decaro, N., Buonavoglia, C., Hajjema, B.J., Rottier, P.J., Buonavoglia, C., Hajjema, B.J., de Groot, R.J., 2008. Gain, preservation, and loss of a group 1 coronavirus accessory glycoprotein. J. Virol. 82 (20), 10312–10317.

Lai, M.M.C., Holmes, K.V., 2001. Coronaviridae: The Viruses and Their Replication. Fields Virology Philadelphia (Lippincott Williams and Wilkins).

Ntafis, V., Mari, V., Decaro, N., Papaanastassopoulou, M., Papaioannou, N., Mpatziou, R., Buonavoglia, C., Xyliouri, E., 2011. Isolation, tissue distribution and molecular characterization of two recombinant canine coronavirus strains. Vet. Microbiol. 151 (3–4), 238–244.

Peng, G., Sun, D., Rajashankar, K.R., Qian, Z., Holmes, K.V., Li, F., 2011. Crystal structure of mouse coronavirus receptor-binding domain complexed with its receptor, aminopeptidase N. Proc. Natl. Acad. Sci. USA 108 (26), 10996–10801.

Pratelli, A., Martella, V., Decaro, N., Tinelli, A., Camero, M., Cirone, F., Elia, G., Cavalli, A., Corrente, M., Greco, G., Buonavoglia, D., Gentile, M., Tempesta, M., Buonavoglia, C., 2003. Genetic diversity of a canine coronavirus detected in pups with diarrhoea in Italy. J. Virol. Methods 110 (1), 9–17.

Pratelli, A., Tempesta, M., Roperto, F.P., Sagazio, P., Carmichael, L., Buonavoglia, C., Pratelli, A., Martella, V., Decaro, N., Tinelli, A., Camero, M., Cirone, F., Elia, G., Cappiello, C., Corrente, M., Greco, G., Buonavoglia, D., Gentile, M., Tempesta, M., Buonavoglia, C., 1999. Fatal coronavirus infection in puppies following canine parvovirus 2b infection. J. Vet. Diagn. Invest. Nov. 11 (6), 550–553.

Regan, A.D., Ousterout, D.G., Whittaker, G.R., 2010. Feline leucinactid virus is critical for the cellular entry of feline infectious peritonitis virus. J. Virol. 84 (15), 7917–7921.

Regan, A.D., Shraybandi, R., Cohen, R.D., Whittaker, G.R., 2008. Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet. Microbiol. 132 (3–4), 235–248.

Regan, A.D., Whittaker, G.R., 2008. Utilization of DC-SIGN for entry of feline coronaviruses into host cells. J. Virol.

Reguera, J., Orondo, D., Santiago, C., Enjuanes, L., Casasnovas, J.M., 2011. Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis coronavirus spike protein. J. Gen. Virol. 92 (Pt 5), 1117–1126.

Rodriguez-Mongado, J.M., Poulsen, T.R., 2004. Molecular characterization of a virulent canine coronavirus BGF strain. Virus Res. 104 (1), 27–31.

Schulzke, B., Kremp, C., Ballesteros, M.L., Shaw, L., Schauer, R., Enjuanes, L., Herrler, G., 1996. Transmissible gastroenteritis coronavirus, but not the related porcine respiratory coronavirus, has a sialic acid (N-glycolyneuraminic acid) binding activity. J. Virol. 70 (8), 5634–5637.

Tresnan, D.B., Devis, R., Holmes, K.V., 1996. Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I. J. Virol. 70 (12), 8669–8674.
Vennema, H., Poland, A., Foley, J., Pedersen, N.C., 1998. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 243 (1), 150–157.

Wang, Y.Y., Lu, C.P., 2009. Analysis of putative recombination hot sites in the S gene of canine coronaviruses. Acta Virol. 53 (2), 111–120.

Wentworth, D., Holmes, K.V., 2001. Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation. J. Virol. 75 (20), 9741–9752.

Zappulli, V., Caliari, D., Cavicchioli, L., Tinelli, A., Castagnaro, M., 2008. Systemic fatal type II coronavirus infection in a dog: pathological findings and immunohistochemistry. Res. Vet. Sci. Apr. 84 (2), 278–282.

Wentworth, D.E., Holmes, K.V., 2001. Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation. J. Virol. 75 (20), 9741–9752.